Jackson Acquisition Co II

Análisis de la acción Jackson Acquisition Co II (JACS)

$10.855

+0.005 (+0.05%)Al cierre

Loading chart…
Máximo
10.920
Apertura
10.920
Precio medio ponderado por volumen
10.88
Volumen
1.01K
Capitalización
—
Mínimo
10.850
Importe
10.94K
EV/EBITDA, TTM
0.00

Jackson Acquisition Company II is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any industry or geographic location, it intends to focus its search for a target business by concentrating its efforts in identifying businesses with a focus on healthcare services, healthcare technology, or otherwise focused on the healthcare industry. The Company neither engaged in any operations nor generated any revenue.

Análisis de IA of Jackson Acquisition Co II (JACS)

Mantener

Jackson Acquisition Company II (JACS) is currently trading at $10.85, which is very close to its 52-week high of $10.87, indicating limited upside potential. The RSI is at 57.63, suggesting that the stock is neither overbought nor oversold, which is a neutral indicator. However, the forward P/E ratio is 0, indicating a lack of expected earnings growth, which raises concerns about future profitability. The stock has shown a 5-day change of +0.28% and a year-to-date change of +4.13%, reflecting modest performance. The main risk is the current ratio, which has dropped to 0.77, indicating potential liquidity issues. Therefore, while the stock shows some stability, the lack of growth indicators and the liquidity risk suggest that it may be prudent to hold rather than buy at this time.

Métricas de valoración

El PER previsto actual de Jackson Acquisition Co II (JACS) es 0.00, frente a su media de 5 años de 0.00.

PER previsto

Muy infravalorado
Media 5A P/E
0.00
P/E actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.12
P/S actual
0.00
Sobrevalorada
1.23
Infravalorada
-0.99

Escenarios de precio de Alphio AI para JACS

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%JACS

$14.19

Precio del escenario

B

Base

Base · 50%JACS

$12.49

Precio del escenario

B

Bajista

Bajista · 25%JACS

$10.64

Precio del escenario

Ballenas con JACS en cartera

L

Linden Advisors LP

+ Con en carteraJACS

+61.02%

Rentabilidad a 3 meses

G

Glazer Capital, LLC

+ Con en carteraJACS

+3.19%

Rentabilidad a 3 meses

W

W. R. Berkley Corporation

+ Con en carteraJACS

-1.34%

Rentabilidad a 3 meses

W

Wolverine Asset Management, LLC

+ Con en carteraJACS

-16.12%

Rentabilidad a 3 meses

Preguntas frecuentes sobre JACS, respondidas por Alphio AI

Jackson Acquisition Company II is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any industry or geographic location, it intends to focus its search for a target business by concentrating its efforts in identifying businesses with a focus on healthcare services, healthcare technology, or otherwise focused on the healthcare industry. The Company neither engaged in any operations nor generated any revenue. It operates in the Financials sector.

Jackson Acquisition Company II (JACS) is currently trading at $10.85, which is very close to its 52-week high of $10.87, indicating limited upside potential. The RSI is at 57.63, suggesting that the stock is neither overbought nor oversold, which is a neutral indicator. However, the forward P/E ratio is 0, indicating a lack of expected earnings growth, which raises concerns about future profitability. The stock has shown a 5-day change of +0.28% and a year-to-date change of +4.13%, reflecting modest performance. The main risk is the current ratio, which has dropped to 0.77, indicating potential liquidity issues. Therefore, while the stock shows some stability, the lack of growth indicators and the liquidity risk suggest that it may be prudent to hold rather than buy at this time.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar